The chemical register
29 amino acids: the Sermorelin catalogue entry
A surprisingly short fragment of a hormone, a collection of altered relatives, and a reputation that has grown much larger than the molecule.
The sermorelin peptide
The satisfying thing about sermorelin is how much of its identity fits into a small piece of chemical shorthand: GHRH(1-29). It copies the first 29 amino acids of growth-hormone-releasing hormone, the message that normally prompts the pituitary gland to release growth hormone. Amino acids are the linked building blocks of a peptide. This fragment is the shortest one retaining full activity at the GHRH receptor.
I like that economy. A shortened molecule can still carry the working message. The acetate in sermorelin acetate describes its salt form; the interesting biological identity remains the fragment. The word “chemical” earns its place here because the small distinctions in these names have real consequences.
Sermorelin mechanism of action
At the pituitary, sermorelin activates the GHRH receptor and its cAMP/PKA signalling pathway. Growth hormone is released in pulses, and the liver responds by producing IGF-1 (insulin-like growth factor 1). Somatostatin and IGF-1 continue to provide feedback that limits further release. The review of GHRH biology and its analogues puts that chemistry in its wider setting.
A secretagogue is simply something that prompts secretion. That is the useful distinction from supplying growth hormone directly: sermorelin prompts the gland to supply its own. Walker’s argument for this feedback-preserving approach is appealing to me as physiology. His paper is an editorial, so the proposed clinical advantage still needs comparative results.
The altered relatives
I expected the little suffixes in the older papers to be a nuisance. They turned out to be the story. Replacing an amino acid with D-Ala2 prolonged the peptide’s half-life in healthy men. Another set of experiments used the [Nle27] analogue; a cognition trial used tesamorelin. These are chemically related entries with different experiments attached to them.
The tesamorelin trial in older adults is particularly easy to misfile under sermorelin. Its hormone and cognition findings deserve attention under the name of the drug actually given. The sermorelin and IGF-1 records give the native fragment and tesamorelin different clinical histories.
Childhood growth and adult aging
Sermorelin’s clinical history includes a concrete outcome: faster first-year growth in prepubertal children with growth-hormone deficiency. The pediatric clinical review describes its diagnostic and treatment roles. In older men, Corpas and colleagues measured increased GH and IGF-1 over 14 days. Height gained by a child and hormones measured in an adult answer very different questions.
I give the childhood result more weight than the broad rejuvenation claims. It names a deficiency, a population and an outcome that matters to that population. The caution about using secretagogues against aging remains relevant to the much larger adult reputation.
The catalogue drawers
The ipamorelin comparison turns on receptor identity. CJC-1295 raises the question of how a chemical modification extends action. The dosage record brings together the studied amounts, absorption and half-life, while sleep accounts and side effects cover the messier reports around the experiments.
The research is specific enough to be interesting without a promise of becoming younger. My question for sermorelin concerns everyday function over a long adult trial; another hormone percentage leaves that question open.
Hormones & trial populations
Children’s growth, older men’s IGF-1 and the tesamorelin findings that travel under the wrong name.
Open this drawer ›Time & absorption
The peptide leaves quickly. The growth-hormone response can last much longer.
Read the timing record ›Related compounds
Ipamorelin’s receptor and CJC-1295’s prolonged action make different comparisons.
Compare the identities ›